Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE versus XARACOLL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE versus XARACOLL.
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE vs XARACOLL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is a sodium channel blocker that stabilizes neuronal membranes and inhibits action potentials, providing local anesthesia. Epinephrine is an alpha- and beta-adrenergic agonist that causes vasoconstriction, prolonging lidocaine's effect and reducing systemic absorption.
XARACOLL (bupivacaine and meloxicam) is a fixed-dose combination product for local analgesia. Bupivacaine is an amide local anesthetic that blocks sodium ion channels, inhibiting nerve impulse conduction. Meloxicam is an NSAID that inhibits cyclooxygenase (COX) isoforms, reducing prostaglandin synthesis.
Local anesthesia: 1% or 2% solution with epinephrine 1:100,000 or 1:200,000; maximum dose 7 mg/kg lidocaine (500 mg) in adults; administer by infiltration or nerve block, not to exceed 1 hour between doses.
Adults: Single dose of 1.3 g (two microspheres) applied intraoperatively directly to the subcutaneous tissue before wound closure.
None Documented
None Documented
Lidocaine: terminal elimination half-life is approximately 1.5–2.0 hours. With continuous infusion or hepatic impairment, half-life may be prolonged (up to 4–6 hours). Epinephrine: plasma half-life is about 2–3 minutes due to rapid uptake and metabolism.
Terminal elimination half-life is approximately 2-4 hours; clinical context: methadone-like opioid, prolonged half-life in elderly, renal impairment, or hepatic impairment; requires monitoring for accumulation.
Lidocaine is primarily metabolized in the liver; approximately 90% of a dose is excreted in the urine as metabolites (including monoethylglycinexylidide and glycinexylidide), with less than 10% excreted unchanged. Epinephrine is metabolized by catechol-O-methyltransferase and monoamine oxidase, with metabolites excreted in urine.
Primarily hepatic metabolism followed by renal excretion of metabolites; approximately 70-80% eliminated in urine (metabolites), <15% unchanged in feces via biliary excretion.
Category A/B
Category C
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic